A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions
Cancers · 26.09.2025 · 17 (19) · 3139
DOI: 10.3390/cancers17193139 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.09.2025. Verfasst von Supriya Peshin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: William Paul Skelton IV.
Abstract (Originalsprache)
Renal cell carcinoma (RCC) is a biologically diverse malignancy with a rising global incidence and a high propensity for metastasis, particularly in its clear cell subtype. While traditional treatments have centered on surgery and targeted therapies, immunotherapy has emerged as a transformative approach in the management of advanced RCC. This review explores the evolution of immunotherapy in RCC, from early cytokine-based treatments to the advent of immune checkpoint inhibitors (ICIs) and their integration with tyrosine kinase inhibitors (TKIs). We detail the immunologic mechanisms underpinning these therapies, the rationale from preclinical models, and the pivotal clinical trials that redefined standard of care. Challenges such as immune resistance, tumor heterogeneity, and immune escape mechanisms are critically analyzed, highlighting tumor-intrinsic and microenvironmental factors. Lastly, we examine ongoing innovations including novel immune checkpoints, cytokine modulators, CAR-T therapies, and neoantigen-based vaccines, offering a forward-looking perspective on enhancing immunotherapeutic efficacy and personalization in RCC management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA.
- Department of Internal Medicine, HCA Florida Oak Hill Hospital, Brooksville, FL 34613, USA.
- Department of Hematology and Oncology, Lincoln Memorial University, Harrogate, TN 38105, USA.
- Department of Medicine, Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Charlottesville, VA 22908, USA.
ORCID-Profile: Supriya Peshin, William Paul Skelton
Förderung
- William Paul Skelton IV
Zitieren
APA
Peshin, S., Dharia, A., Moka, N., & Skelton, W. P. (2025). A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions. Cancers, 17(19), 3139. https://doi.org/10.3390/cancers17193139
Vancouver
Peshin S, Dharia A, Moka N, Skelton WP. A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions. Cancers. 2025;17(19):3139. doi:10.3390/cancers17193139
BibTeX
@article{Peshin2025,
author = {Peshin, Supriya and Dharia, Adit and Moka, Nagaishwarya and Skelton, William Paul},
title = {A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions},
journal = {Cancers},
year = {2025},
volume = {17},
number = {19},
pages = {3139},
doi = {10.3390/cancers17193139}
}
EUVIMED